Drug Profile
Interferon gamma human recombinant - Pharmaclon
Alternative Names: IngaronLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Pharmaclon
- Class Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Interferons; Lymphokines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cancer; Chlamydial infections; Chronic granulomatous disease; Genital warts; Hepatitis B; Hepatitis C; Herpes zoster; Herpesvirus infections; HIV infections; Prostatitis; Tuberculosis
- No development reported Community-acquired pneumonia
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for clinical-Phase-Unknown development in Community-acquired-pneumonia in Russia (IM)
- 04 Jun 2015 Efficacy and adverse events data from clinical trials in Herpes infection released by Pharmaclon before June 2015
- 04 Jun 2015 Efficacy and adverse events data from clinical trials in Chlamydial infections released by Pharmaclon before June 2015